Comparison of Radiation Pneumonitis in Lung Cancer Patients Treated with HT versus IMRT and Circulating Lymphocyte Subsets as Predicting Risk Factors

Xin Zhang,* Dingyi Yang,* Yong Jiang, Luo Huang, Can Wang, Dan Tao, Xianfeng Liu, Yongyang Lei, Yongzhong Wu, Wei Zhou Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, People’s Repu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zhang X, Yang D, Jiang Y, Huang L, Wang C, Tao D, Liu X, Lei Y, Wu Y, Zhou W
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
Acceso en línea:https://doaj.org/article/68667240322041c78b2ec67af3ebde3f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:68667240322041c78b2ec67af3ebde3f
record_format dspace
spelling oai:doaj.org-article:68667240322041c78b2ec67af3ebde3f2021-12-02T15:09:50ZComparison of Radiation Pneumonitis in Lung Cancer Patients Treated with HT versus IMRT and Circulating Lymphocyte Subsets as Predicting Risk Factors1178-7031https://doaj.org/article/68667240322041c78b2ec67af3ebde3f2021-08-01T00:00:00Zhttps://www.dovepress.com/comparison-of-radiation-pneumonitis-in-lung-cancer-patients-treated-wi-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Xin Zhang,* Dingyi Yang,* Yong Jiang, Luo Huang, Can Wang, Dan Tao, Xianfeng Liu, Yongyang Lei, Yongzhong Wu, Wei Zhou Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yongzhong Wu; Wei ZhouChongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, 181 Han Yu Road, Chongqing, 400030, People’s Republic of ChinaTel +86 18323064006Email cqmdwyz@163.com; 1052308491@qq.comPurpose: We sought to compare the symptomatic radiation pneumonitis (RP) in lung cancer patients treated with helical tomotherapy (HT) versus intensity-modulated radiotherapy (IMRT), and examine the predictive value of circulating lymphocyte subsets affecting the occurrence of RP.Patients and Methods: Circulating lymphocyte subsets, clinical characteristics, dosimetric parameters and pulmonary function were collected from 130 lung cancer patients treated with HT (n = 53) or IMRT (n = 77) from 2016 through 2020. Symptomatic RP was compared between groups. Binary logistic regression was used to identify predictors of RP.Results: The IMRT group had larger planning target volume (319.9 vs 240.8 cc, P = 0.041); more ECOG performance status 0– 1 (96.1% vs 79.2%, P = 0.002); more stage III–IV disease (94.8% vs 37.6%, P = 0.028); and more combined systemic therapy (85.7% vs 69.8%, P = 0.022). Grade ≥ 2 RP were comparable between IMRT and HT groups (16.9% vs 15.1%, P = 0.785). For stage III–IV disease, IMRT was associated with lower lung V10 (31.9% vs 35.8%, P = 0.047) and lower incidence of grade 5 RP (0% vs 9.1%, P = 0.018). All lymphocyte subsets reduced after radiotherapy. The decrease degree of total T cell count and CD4+ T cell count were larger after IMRT than HT (P = 0.043, P = 0.021). In univariate analysis, the smoking status, lower baseline FEV1, and higher total T cell count, higher CD8+ T cell count, lower total B cell count, lower CD4+/CD8+ ratio after radiotherapy were associated with the development of grade ≥ 2 RP. The higher CD8+T cell count after radiotherapy was the only risk factor associated with grade ≥ 2 RP in multivariable analysis (OR 1.003; 95% CI: 1.000– 1.005; P = 0.044).Conclusion: IMRT was associated with lower lung V10 and less grade 5 RP than HT for stage III–IV lung cancer. Higher CD8+ T cell count after radiotherapy was associated with an increased risk of RP. HT may better preserve total T cell and CD4+ T cell than IMRT.Keywords: radiation pneumonitis, lung cancer, helical tomotherapy, intensity-modulated radiotherapy, circulating lymphocyteZhang XYang DJiang YHuang LWang CTao DLiu XLei YWu YZhou WDove Medical Pressarticleradiation pneumonitislung cancerhelical tomotherapyintensity modulated radiotherapycirculating lymphocytePathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 4205-4215 (2021)
institution DOAJ
collection DOAJ
language EN
topic radiation pneumonitis
lung cancer
helical tomotherapy
intensity modulated radiotherapy
circulating lymphocyte
Pathology
RB1-214
Therapeutics. Pharmacology
RM1-950
spellingShingle radiation pneumonitis
lung cancer
helical tomotherapy
intensity modulated radiotherapy
circulating lymphocyte
Pathology
RB1-214
Therapeutics. Pharmacology
RM1-950
Zhang X
Yang D
Jiang Y
Huang L
Wang C
Tao D
Liu X
Lei Y
Wu Y
Zhou W
Comparison of Radiation Pneumonitis in Lung Cancer Patients Treated with HT versus IMRT and Circulating Lymphocyte Subsets as Predicting Risk Factors
description Xin Zhang,* Dingyi Yang,* Yong Jiang, Luo Huang, Can Wang, Dan Tao, Xianfeng Liu, Yongyang Lei, Yongzhong Wu, Wei Zhou Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yongzhong Wu; Wei ZhouChongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, 181 Han Yu Road, Chongqing, 400030, People’s Republic of ChinaTel +86 18323064006Email cqmdwyz@163.com; 1052308491@qq.comPurpose: We sought to compare the symptomatic radiation pneumonitis (RP) in lung cancer patients treated with helical tomotherapy (HT) versus intensity-modulated radiotherapy (IMRT), and examine the predictive value of circulating lymphocyte subsets affecting the occurrence of RP.Patients and Methods: Circulating lymphocyte subsets, clinical characteristics, dosimetric parameters and pulmonary function were collected from 130 lung cancer patients treated with HT (n = 53) or IMRT (n = 77) from 2016 through 2020. Symptomatic RP was compared between groups. Binary logistic regression was used to identify predictors of RP.Results: The IMRT group had larger planning target volume (319.9 vs 240.8 cc, P = 0.041); more ECOG performance status 0– 1 (96.1% vs 79.2%, P = 0.002); more stage III–IV disease (94.8% vs 37.6%, P = 0.028); and more combined systemic therapy (85.7% vs 69.8%, P = 0.022). Grade ≥ 2 RP were comparable between IMRT and HT groups (16.9% vs 15.1%, P = 0.785). For stage III–IV disease, IMRT was associated with lower lung V10 (31.9% vs 35.8%, P = 0.047) and lower incidence of grade 5 RP (0% vs 9.1%, P = 0.018). All lymphocyte subsets reduced after radiotherapy. The decrease degree of total T cell count and CD4+ T cell count were larger after IMRT than HT (P = 0.043, P = 0.021). In univariate analysis, the smoking status, lower baseline FEV1, and higher total T cell count, higher CD8+ T cell count, lower total B cell count, lower CD4+/CD8+ ratio after radiotherapy were associated with the development of grade ≥ 2 RP. The higher CD8+T cell count after radiotherapy was the only risk factor associated with grade ≥ 2 RP in multivariable analysis (OR 1.003; 95% CI: 1.000– 1.005; P = 0.044).Conclusion: IMRT was associated with lower lung V10 and less grade 5 RP than HT for stage III–IV lung cancer. Higher CD8+ T cell count after radiotherapy was associated with an increased risk of RP. HT may better preserve total T cell and CD4+ T cell than IMRT.Keywords: radiation pneumonitis, lung cancer, helical tomotherapy, intensity-modulated radiotherapy, circulating lymphocyte
format article
author Zhang X
Yang D
Jiang Y
Huang L
Wang C
Tao D
Liu X
Lei Y
Wu Y
Zhou W
author_facet Zhang X
Yang D
Jiang Y
Huang L
Wang C
Tao D
Liu X
Lei Y
Wu Y
Zhou W
author_sort Zhang X
title Comparison of Radiation Pneumonitis in Lung Cancer Patients Treated with HT versus IMRT and Circulating Lymphocyte Subsets as Predicting Risk Factors
title_short Comparison of Radiation Pneumonitis in Lung Cancer Patients Treated with HT versus IMRT and Circulating Lymphocyte Subsets as Predicting Risk Factors
title_full Comparison of Radiation Pneumonitis in Lung Cancer Patients Treated with HT versus IMRT and Circulating Lymphocyte Subsets as Predicting Risk Factors
title_fullStr Comparison of Radiation Pneumonitis in Lung Cancer Patients Treated with HT versus IMRT and Circulating Lymphocyte Subsets as Predicting Risk Factors
title_full_unstemmed Comparison of Radiation Pneumonitis in Lung Cancer Patients Treated with HT versus IMRT and Circulating Lymphocyte Subsets as Predicting Risk Factors
title_sort comparison of radiation pneumonitis in lung cancer patients treated with ht versus imrt and circulating lymphocyte subsets as predicting risk factors
publisher Dove Medical Press
publishDate 2021
url https://doaj.org/article/68667240322041c78b2ec67af3ebde3f
work_keys_str_mv AT zhangx comparisonofradiationpneumonitisinlungcancerpatientstreatedwithhtversusimrtandcirculatinglymphocytesubsetsaspredictingriskfactors
AT yangd comparisonofradiationpneumonitisinlungcancerpatientstreatedwithhtversusimrtandcirculatinglymphocytesubsetsaspredictingriskfactors
AT jiangy comparisonofradiationpneumonitisinlungcancerpatientstreatedwithhtversusimrtandcirculatinglymphocytesubsetsaspredictingriskfactors
AT huangl comparisonofradiationpneumonitisinlungcancerpatientstreatedwithhtversusimrtandcirculatinglymphocytesubsetsaspredictingriskfactors
AT wangc comparisonofradiationpneumonitisinlungcancerpatientstreatedwithhtversusimrtandcirculatinglymphocytesubsetsaspredictingriskfactors
AT taod comparisonofradiationpneumonitisinlungcancerpatientstreatedwithhtversusimrtandcirculatinglymphocytesubsetsaspredictingriskfactors
AT liux comparisonofradiationpneumonitisinlungcancerpatientstreatedwithhtversusimrtandcirculatinglymphocytesubsetsaspredictingriskfactors
AT leiy comparisonofradiationpneumonitisinlungcancerpatientstreatedwithhtversusimrtandcirculatinglymphocytesubsetsaspredictingriskfactors
AT wuy comparisonofradiationpneumonitisinlungcancerpatientstreatedwithhtversusimrtandcirculatinglymphocytesubsetsaspredictingriskfactors
AT zhouw comparisonofradiationpneumonitisinlungcancerpatientstreatedwithhtversusimrtandcirculatinglymphocytesubsetsaspredictingriskfactors
_version_ 1718387756747456512